Abstract: Phenylpiperazine derivatives having high affinity for the &agr;1-adrenoreceptor and pharmaceutical compositions containing them. Also disclosed is a method of using the such derivatives to treat benign prostatic hyperplasia.

Abstract: The invention concerns a pharmaceutical composition containing, as active principle, at least one NO syntase inhibiting substance and at least one oxygen reactive form trapping substance, optionally with a pharmaceutically acceptable support. The invention also concerns a product containing at least one NO syntase inhibiting substance and at least one oxygen reactive form trapping substance as combined product of these active principles in separate form.

Abstract: Novel compounds having one group 13 element bound with one mono- or di-anionic tridentate ligand, a method of preparation thereof and use thereof as a copolymerization catalyst.

Abstract: This invention relates to the use of ginkgolides and extracts of Ginkgo biloba for inhibiting the membrane expression of benzodiazepine receptors and for inhibiting the release of glucocorticoids in a patient.

Abstract: This invention relates to a process for preparing biodegradable microspheres and or nanospheres using an oil-in-water process for the controlled release of bioactive peptides.

Abstract: The present invention is directed to novel analogues of PACAP (Pituitary Adenylate Cyclase Activating Polypeptide) as described in the specification, which are agonists of the PACAP receptor and as such are useful in treating cerebrovascular ischemia, male impotence, motor neuron disease, neuropathy, pain, depression, anxiety disorders, brain trauma, memory impairments, dementia, cognitive disorder, central nervous system diseases (such as Parkinson's disease, Alzheimer's disease), migraine, neurodegenerative diseases, ischemic heart disease, myocardial infarction, fibrosis, restenosis, diabetes mellitus, muscle disease, gastric ulcer, stroke, atherosclerosis, hypertension, septic shock, thrombosis, retina disease, cardiovascular disease, renal failure and cardiac failure and the prevention of neuronal cell death in a mammal. This invention is also directed to pharmaceutical compositions useful therefor.

Abstract: The invention concerns a Ginkgo biloba leaf flavonoid extract and more specifically an extract which is terpene free and/or has a high flavonoid heteroside content. The invention also concerns a flavoring compound containing such an extract and the use of this extract as a flavoring ingredient. The invention finally concerns a process for obtaining a substantially terpene-free Ginkgo biloba leaf flavonoid extract.

Abstract: A cross-linked copolymer based on at least one non-crosslinked polycarboxylic polysaccharide and at least one second non-crosslinked polycarboxylic polymer which is not a polycarboxylic polysaccharide and a cross-linking agent having at least two amine functions.

Abstract: Disclosed is a sustained release pharmaceutical composition. The composition includes a polyester containing a free COOH group ionically conjugated with a bioactive polypeptide comprising at least one effective ionogenic amine, wherein at least 50% by weight of the polypeptide present in the composition is ionically conjugated to the polyester.

Abstract: A method of inhibiting effects of neurotoxic products in warm-blooded animals comprising administering to warm-blooded animals an amount of 2-methyl-1-(1-piperidinyl)-1-(2-thienyl)-cyclohexane in substantially pure racemic, diastereoisomeric or enantiomeric form effect to inhibit effects of neurotropic products and mixtures of thienyl cyclohexylamine and at least one member of the group consisting of anticholinergic, anticonvulsant or cholinesterase-reactivating substances.

Abstract: The invention concerns the use of a flavonoidic extract of ginkgo biloba leaves, and more specifically an extract designed for oral hygiene. The invention also concerns a composition for oral hygiene containing such an extract.

Abstract: Novel method for treating warm-blooded animals for inducing anti-emetic activity, accelerating gastric emptying, modifying intestinal transit and anxiety, depression and sleep disorders by administration of a compound of the formula ##STR1## wherein Ar is unsubstituted or substituted phenyl, R is alkyl of 1 to 10 carbon atoms or cycloalkyl of 3 to 10 carbon atoms and its acid addition salts.

Abstract: The invention relates to new glycosylated derivatives of ginkgolides, their use as medicaments and the pharmaceutical compositions containing them. The invention also provides a preparation process for these derivatives.

Abstract: A compound selected from the group consisting of a compound of the formula ##STR1## wherein the substituents are defined as in the application and its non-toxic, pharmaceutically acceptable acid addition salts which are useful for treating hypertension.

Abstract: The invention concerns novel phenoxyethylamine derivatives having a high affinity for the 5-HT.sub.1A receptor, methods for preparing them, pharmaceutical compositions containing them and their use as medicine and particularly as inhibitors of gastric acid secretion or as antiemetic.

Abstract: A sustained release drug formulation including: a drug; a biodegradable polymer which is insoluble in water; and an oil vehicle in which both the drug and the polymer are dissolved. The oil vehicle contains 10-100% by volume a pharmaceutically acceptable oil and 0-90% by volume a pharmaceutically acceptable liquid carrier for the drug or the polymer.

Abstract: A camptothecin analog characterized in that the hydroxy lactone of the camptothecin is a .beta.-hydroxy lactone or the corresponding .beta.-hydroxyacid, resulting from the opening of said lactone, or a derivative of said .beta.-hydroxyacid, or a Pharmaceutically acceptable salt thereof, is disclosed. In particular, compounds of formulae (I) and (II) are disclosed. Methods for preparing the compounds of formulae (I) and (II), pharmaceutical compositions containing said containing said compounds, and their use, particularly as topoisomerase inhibitors and antitumoral drugs, are also disclosed.

Abstract: Antisense oligonucleotides that selectively hybridise with one or more genes necessary for Helicobacter pylori (H. pylori) activity, and particularly with the CagA cytotoxicity-associated immunodominant antigen, flagellin (flaA and flaB) or vacuolating cytotoxin (vacA), are disclosed. Pharmaceutical compositions containing said antisense oligonucleotides, and the use thereof for treating atrophic gastritis, peptic and duodenal ulcers, gastric atrophy or stomach cancer, are also disclosed.

Abstract: Novel galanthamine derivatives of general fonnulae (Ia) and (Ib), a method for preparing same, pharmaceutical compositions containing said derivatives, and their use, in particular as cholinesterase inhibitors, are disclosed.

Abstract: Peptide variants of fragment of parathyroid hormone (PTH) or parathyroid hormone-related protein (PTHrP), in which at least one of the amino acid residues is replaced with Acc.